Federal Register / Vol. 62, No. 41 / Monday, March 3, 1997 / Notices 9441

federally funded health care program. If

resolution results in conviction,

debarment or exclusion of the

individual, the laboratory should

terminate its employment of that

individual or company.

Conclusion

These basic recommended elements

coupled with other published

regulations and guidelines are the

foundation for a comprehensive

compliance plan for clinical

laboratories. On advice from in-house

counsel and senior management,

clinical laboratories should add to or

modify these elements to better reflect

the corporate structure of the laboratory,

its mission, and its employee

composition. The OIG believes that by

implementing an effective compliance

plan, a laboratory will achieve better

quality control of claims submission

and reduce the risk of future criminal

and civil liabilities.

Dated: February 24, 1997.

June Gibbs Brown,

Inspector General.

[FR Doc. 97–5192 Filed 2–28–97; 8:45 am]

BILLING CODE 4150–04–P

National Institutes of Health

Notice of Meeting of the Advisory

Committee on Blood Safety and

Availability

Pursuant to Pub. L 92–463, notice is

hereby given of the meeting of the

Advisory Committee on Blood Safety

and Availability, Department of Health

and Human Services, March 20–21,

1997. This meeting will be held at the

National Institutes of Health, Warren G.

Magnuson Clinical Center, Jack Masur

Auditorium, 9000 Rockville Pike,

Bethesda, Maryland 20892.

The entire meeting will be open to the

public from 8:30 a.m. on March 20 to

adjournment on March 21. On March

20, the Committee will discuss hepatitis

C virus (HCV) infection, its occurrence

following blood transfusion, other

epidemiology of HCV infection and

appropriate ways of approaching the

public health aspects of this infection.

On March 21, the Committee will

address multiple aspects of the

theoretical possibility that CreutzfeldtJakob disease (CJD) can be transmitted

by blood transfusion. For each topic, a

time will be set aside for the public to

comment. Prospective speakers should

notify the Executive Secretary for this

meeting of their wish to present and

should plan for no more than 5 minutes

of comments.

Contact: Paul R. McCurdy, M.D.

Acting Executive Secretary, Advisory

Committee on Blood Safety and

Availability, Director, Blood Resources

Program, DBDR–MSC–7950, NHLBI,

NIH, Bethesda, Maryland 20892–7950.

Phone: 301/435–0065; Fax 301/480–

1060; E–Mail: paul—mccurdy@nih.gov.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact the Executive Secretary in

advance of the meeting.

Dated: February 25, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–5164 Filed 2–28–97; 8:45 am]

BILLING CODE 4140–01–M

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meeting

of the National Cancer Institute Initial

Review Group:

Agenda/Purpose: To review and evaluate

grant applications.

Committee Name: Subcommittee H—

Clinical Trials Subcommittee.

Date: April 8–9, 1997.

Time: 8 a.m.

Place: Buffalo Marriott, 1340 Millersport

Highway, Amherst, New York 14221.

Contact Person: John L. Meyer, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, 6130 Executive Blvd.

Room 611C, Bethesda, Md 20892, Telephone:

301–496–7721.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.

Applications and/or proposals and the

discussion could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower,

93.399, Cancer Control)

Dated: February 25, 1997.

LaVerne Y. Springfield,

Committee Management Officer, NIH.

[FR Doc. 97–5166 Filed 2–28–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Arthritis and

Musculoskeletal and Skin Diseases;

Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute of Arthritis and

Musculoskeletal and Skin Diseases

Special Emphasis Panel (SEP) meetings:

Name of SEP: NIAMS Supplemental

(Teleconference).

Date: March 18, 1997.

Time: 11:00 a.m.–12:30 p.m.

Place: Natcher Building, 45 Center Drive,

Rm 5AS–25U.

Contact Person: Aftab A. Ansari, Ph.D.,

Natcher Building, 45 Center Drive, Rm 5AS–

25U, Bethesda, Maryland 20892–6500,

Telephone: 301–594–4952.

Name of SEP: NIAMS Program Project.

Date: April 1, 1997.

Time: 8:30 a.m.–adjournment.

Place: Bethesda Marriott, 5151 Pooks Hill

Road, Bethesda, Maryland 20814.

Contact Person: Aftab A. Ansari, Ph.D.,

Natcher Building, 45 Center Drive, Rm 5AS–

25U, Bethesda, Maryland 20892–6500,

Telephone: 301–594–4952.

Purpose/Agenda: To evaluate and review

research grant applications.

These meetings will be closed in

accordance with the provisions set forth in

sections 552b(c)(4) and 552b(c)(6), Title 5

U.S.C. The discussion of these applications

could reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with the

applications, the disclosure of which would

constitute a clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. [93.846, Project Grants in

Arthritis, Musculoskeletal and Skin Diseases

Research], National Institutes of Health,

HHS)

Dated: February 25, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–5163 Filed 2–28–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Mental Health;

Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings of the National Institute of

Mental Health Special Emphasis Panel:

Agenda Purpose: To review and evaluate

grant applications.

Committee Name: National Institute of

Mental Health Special Emphasis Panel.

Date: March 17, 1997.

Time: 11 a.m.

Place: Parklawn, Room 9–101, 5600

Fishers Lane, Rockville, MD 20857.